Announced details
Adenovirus infection following hematopoietic stem cell transplantation. Intended for patients who do not meet the eligibility criteria for clinical trials, have no alternative treatment and are in life-threatening condition
No impact on consolidated results for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (BCV) |
| Launch date | 8 October 2026 (starts today; CUP begins) |
| Applicable area | Adenovirus infection following hematopoietic stem cell transplantation. Intended for patients who do not meet the eligibility criteria for clinical trials, have no alternative treatment and are in life-threatening condition |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending December 2026 |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Requests had been received from patients and their families seeking access to BCV because the patients did not meet the eligibility criteria for clinical trials and were in life-threatening condition without alternative treatment. On humanitarian grounds, the company will provide the unapproved drug under strict eligibility criteria.